Όλο το DSpace

Εμφάνιση απλής εγγραφής

What may constrain the success of indoleamine 2,3-dioxygenase 1 inhibitors in cancer immunotherapy?

dc.creatorEleftheriadis T.en
dc.date.accessioned2023-01-31T07:37:11Z
dc.date.available2023-01-31T07:37:11Z
dc.date.issued2018
dc.identifier10.3389/fimmu.2018.01879
dc.identifier.issn16643224
dc.identifier.urihttp://hdl.handle.net/11615/71307
dc.description.abstract[No abstract available]en
dc.language.isoenen
dc.sourceFrontiers in Immunologyen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85051561900&doi=10.3389%2ffimmu.2018.01879&partnerID=40&md5=fc0924390fa3eaf54ac05b485f45a3bd
dc.subjectcarnitine palmitoyltransferase Ien
dc.subjectcytotoxic T lymphocyte antigen 4en
dc.subjectepacadostaten
dc.subjectglucose transporter 1en
dc.subjectindoleamine 2,3 dioxygenaseen
dc.subjectindoleamine 2,3 dioxygenase 1en
dc.subjectindoleamine 2,3 dioxygenase 1 inhibitoren
dc.subjectkynurenineen
dc.subjectmammalian target of rapamycin complex 1en
dc.subjectoxygenase inhibitoren
dc.subjectpembrolizumaben
dc.subjectprotein p53en
dc.subjecttryptophanen
dc.subjectunclassified drugen
dc.subjectantineoplastic agenten
dc.subjectaromatic hydrocarbon receptoren
dc.subjectEIF2AK4 protein, humanen
dc.subjectindoleamine 2,3 dioxygenaseen
dc.subjectprotein serine threonine kinaseen
dc.subjecttryptophanen
dc.subjectcancer immunotherapyen
dc.subjectdrug efficacyen
dc.subjectenzyme activityen
dc.subjecthumanen
dc.subjectimmune responseen
dc.subjectimmunosurveillanceen
dc.subjectliver cell carcinomaen
dc.subjectlymphocytic infiltrationen
dc.subjectmetastatic melanomaen
dc.subjectNoteen
dc.subjectprotein expressionen
dc.subjecttumor growthen
dc.subjecttumor microenvironmenten
dc.subjectimmunological toleranceen
dc.subjectimmunologyen
dc.subjectimmunomodulationen
dc.subjectimmunotherapyen
dc.subjectmetabolismen
dc.subjectneoplasmen
dc.subjectproceduresen
dc.subjectsignal transductionen
dc.subjectT lymphocyteen
dc.subjectAntineoplastic Agentsen
dc.subjectHumansen
dc.subjectImmune Toleranceen
dc.subjectImmunomodulationen
dc.subjectImmunotherapyen
dc.subjectIndoleamine-Pyrrole 2,3,-Dioxygenaseen
dc.subjectNeoplasmsen
dc.subjectProtein-Serine-Threonine Kinasesen
dc.subjectReceptors, Aryl Hydrocarbonen
dc.subjectSignal Transductionen
dc.subjectT-Lymphocytesen
dc.subjectTryptophanen
dc.subjectFrontiers Media S.A.en
dc.titleWhat may constrain the success of indoleamine 2,3-dioxygenase 1 inhibitors in cancer immunotherapy?en
dc.typeotheren


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής